DOST Imaging May Predict Breast Cancer Response to Chemotherapy

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal Clinical Cancer Research, researchers at Dartmouth College in Hanover, New Hampshire, have found that Diffuse Optical Spectroscopic Tomographic imaging (DOST) may be effective for predicting which patients with breast cancer will have achieve the best response to neoadjuvant chemotherapy prior to surgery.

DOST imaging is a technique that measures the hemoglobin and oxygen saturation levels of tumor tissue. Higher levels indicate the presence of blood vessels that the tumor requires to grow.

The study suggests that patients with higher levels of hemoglobin and oxygen saturation are more likely to respond well to neoadjuvant chemotherapy. In addition, the researchers say that the utilization of DOST imaging during novel neoadjuvant chemotherapy studies could decrease the number of patients required for the study, as well as the duration in which they need to be followed.

The researchers hope to next design a portable and compact DOST imaging technique to measure changes in the breast before and during treatment with chemotherapy. By integrating this system into clinical oncology practice, researchers could potentially increase patient participation in future studies.

DOST Imaging May Predict Breast Cancer Response to Chemotherapy
DOST may be effective for predicting which patients will achieve the best response to chemotherapy.

A Dartmouth study suggests that it may be possible to use Diffuse Optical Spectroscopic Tomographic imaging (DOST) to predict which patients will best respond to chemotherapy used to shrink breast cancer tumors before surgery. These findings could eliminate delays in effective early treatment for tumors unlikely to respond to neoadjuvant chemotherapy (NAC).

The study, "Predicting breast tumor response to neoadjuvant chemotherapy with Diffuse Optical Spectroscopic Tomography prior to treatment," was published online in Clinical Cancer Research on October 7, 2014. Breast cancer is the most common non-skin cancer in women worldwide, and the second leading cause of women's cancer mortality in the United States. A common treatment strategy after diagnosis is to shrink breast cancer tumors larger than 3 centimeters with a 6- to 8-month course of NAC prior to surgery.

READ FULL ARTICLE From Medical Express

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs